Sino Biopharmaceutical (1177.HK) Challenges Multi-Months High After Posting 1Q Result

Sino Biopharmaceutical (1177), a drug maker, announced that 1Q net income grew 0.6% on year to 862 million yuan on revenue of 6.22 billion yuan, up 0.2%.....

Stocks (1)

Sino Biopharmaceutical (1177), a drug maker, announced that 1Q net income grew 0.6% on year to 862 million yuan on revenue of 6.22 billion yuan, up 0.2%. The company declared a quarterly dividend of 0.02 Hong Kong dollar per share.

From a technical point of view, the stock has started its Range Trading since September 2019 on the daily chart. Currently, the stock posts a Long Range Bar after getting support from the rising trend line drawn from March low. The prices are expected to challenge the resistance level at HK$12.44 (the multi months reaction highs level) again.

At this momentum, waiting for a breakout signal is essential to validate that prices would go for another trading zone. A close above HK$12.44 would signal a breakout current consolidation zone and enhance the bullish outlook. The stock could consider a measured move of range to HK$15.40.

However, a break below HK$10.76 (the bottom of April 22) would break a return to HK$9.50 (multi reaction lows level)

Source: GAIN Capital, TradingView

Build your confidence risk free

More from Equities

Join our live webinars for the latest analysis and trading ideas. Register now

StoneX Financial Ltd (trading as “City Index”) is an execution-only service provider. This material, whether or not it states any opinions, is for general information purposes only and it does not take into account your personal circumstances or objectives. This material has been prepared using the thoughts and opinions of the author and these may change. However, City Index does not plan to provide further updates to any material once published and it is not under any obligation to keep this material up to date. This material is short term in nature and may only relate to facts and circumstances existing at a specific time or day. Nothing in this material is (or should be considered to be) financial, investment, legal, tax or other advice and no reliance should be placed on it.

No opinion given in this material constitutes a recommendation by City Index or the author that any particular investment, security, transaction or investment strategy is suitable for any specific person. The material has not been prepared in accordance with legal requirements designed to promote the independence of investment research. Although City Index is not specifically prevented from dealing before providing this material, City Index does not seek to take advantage of the material prior to its dissemination. This material is not intended for distribution to, or use by, any person in any country or jurisdiction where such distribution or use would be contrary to local law or regulation.

For further details see our full non-independent research disclaimer and quarterly summary.